Hypoactive Sexual Desire Disorder (HSDD) is the most common female sexual dysfunction. The diagnosis of HSDD requires the existence of personal distress or interpersonal difficulties associated with low sexual desire, that cannot be explained by any other psychiatric affection and that is not exclusively due to a disease or substance. HSDD can have a serious effect on emotional wellbeing and interpersonal relationships, and it occurs in premenopausal and postmenopausal women. The Decreased Sexual Desire Screener is a shortened diagnostic method designed to help doctors who are not specialized in female sexual dysfunction to diagnose acquired HSDD in women. There is evidence that treatment with androgens or with estrogens is effective in HSDD; however, important unanswered questions still exist. Presently, new therapeutic strategies to combat HSDD are being researched, including novel methods of testosterone provision and drugs that act upon the CNS.
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, (4th Edition), Text Revision. American Psychiatric Press, Washington, DC, USA (2000).
5.
Discusses classifications and diagnosis.
6.
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, (2nd Edition): American Psychiatric Press, Washington, DC (1968).
7.
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, (3rd Edition), Revision. American Psychiatric Press, Washington, DC, USA (1987).
8.
BassonRBermanJBurnettA: Report of the international consensus development conference on female sexual dysfunction: definitions and classifications. J. Urol.163, 888–893 (2000).
9.
Discusses female sexual dysfunctiondiagnostic and classification system based on physiological as well as psycological pathophisiologies and personal distress criterion.
10.
CarvalheiraAABrottoLALealI: Women's motivations for sex: exploring the diagnostic and statistical manual, fourth edition, text revision criteria for hypoactive sexual desire and female sexual arousal disorders. J. Sex. Med.7(4 Pt 1), 1454–1463 (2010).
11.
ShifrenJLMonzBURussoPASegretiAJohannesCB: Sexual problems and distress in United States women: prevalence and correlates. Obstet. Gynecol.112, 970–978 (2008).
12.
Survey on the prevalence of female sexual dysfunction from a national research panel representative of US women.
13.
DennersteinLKoochakiPBartonIGraziottinA: Hypoactive sexual desire disorder in menopausal women: a survey of western European women. J. Sex. Med.3, 212–222 (2006).
14.
Cross sectional survey of 2.467 European women aged 20-70 years on Hypoactive Sexual Desire Disorder (HSDD).
15.
LeiblumSRKoochakiPERodenbergCABartonIPRosenRC: Hypoactive Sexual Desire Disorder in postmenopausal women: US results from the Women's International Study of Health and Sexuality (WISHeS). Menopause13, 46–56 (2006).
16.
Important survey to determine the prevalence of HSDD among US women by reproductive status and age and to explore the correlates of sexually related distress.
17.
Castelo-BrancoCPalaciosSCombaliaJFerrerMTraveriaG: Risk of hypoactive sexual desire disorder and associated factors in a cohort of oophorectomized women. Climacteric12(6), 525–532 (2009).
18.
DennersteinLHayesRDSandMLehertP: Attitudes towards and frequency of partner interactions among women reporting decreased sexual desire. J. Sex. Med.6, 1668–1673 (2009).
19.
GraziottinALeiblumSR: Biological and psychosocial pathophysiology of female sexual dysfunction during the menopausal transition. J. Sex. Med.2(Suppl. 3), 133–145 (2005).
20.
HayesRDDennersteinLBennettCMSidatMGurrinLCFairleyCK: Risk factors for female sexual dysfunction in the general population: exploring factors associated with low sexual function and sexual distress. J. Sex. Med.5, 1681–1693 (2008).
21.
HayesRDDennersteinLBennettCMKoochakiPELeiblumSRGraziottinA: Relationship between Hypoactive Sexual Desire Disorder and aging. Fertil. Steril.87, 107–112 (2007).
22.
SaloniaAZanniGNappiRE: Sexual dysfunction is common in women with lower urinary tract symptoms and urinary incontinence: results of a cross-sectional study. Eur. Urol.45(5), 642–648 (2004).
23.
ClaytonAH: Female sexual dysfunction related to depression and antidepressant medications. Curr. Womens Health Rep.2, 182–187 (2002).
24.
SeratiMSalvatoreSSiestoG: Female sexual function during pregnancy and after childbirth. J. Sex. Med. (2010) (Epub ahead of print).
25.
ClaytonAH: The pathophysiology of hypoactive sexual desire disorder in women. Int. J. Gynaecol. Obstet.110(1), 7–11(2010).
26.
SoaresCNPoitrasJRProutyJ: Effect of reproductive hormones and selective estrogen receptor modulators on mood during menopause. Drugs Aging20(2), 85–100 (2003).
27.
WyckoffMHChamblissKLMineoC: Plasmamembrane estrogen receptors are coupled to endhotelial nitric-oxide synthase throughGa. J. Biol. Chem.276(29), 27071–27076 (2001).
28.
MarinREscrigAAbreuPMasM: Androgen-dependent nitric oxide release in rat penis correlates with levels of constitutive nitric oxide synthase isoenzymes. Biol. Reprod.61(4), 1012–1016 (1999).
29.
DavisSRDavisonSLDonathSBellRJ: Circulating androgen levels and self-reported sexual function in women. JAMA294, 91–96 (2005).
30.
Analysis to determine wether women withlow self-reported sexual desire and sexual satisfaction are more likely to have low serum androgen levels that women without self-reported low sexual desire and sexual satisfaction.
31.
BassonRMcInnesRSmithMDHodgsonGKoppikerN: Efficacy and safety of sildenafil citrate in women with sexual dysfunction associated with female sexual arousal disorder: Vancouver Hospital and Health Sciences Center, British Columbia, Canada. J. Womens Health Gend. Based Med.11(4), 367–377 (2002).
32.
PerelmanMA: Female sexual dysfunction and the central nervous system. J. Sex. Med.4, 257–259 (2007).
33.
HullEMLorrainDSDuJMatuszewichLLumleyLAPutnamSK: Hormoneneurotransmitter interactions in the control of sexual behavior. Behav. Brain Res.105, 105–116 (1999).
34.
Provides important physiological data on neurotransmitters, special dopamine on sexual behavior.
35.
HalarisA: Neurochemical aspects of the sexual response cycle. CNS Spectr.8, 211–216 (2003).
36.
KrugerTHHaakePHartmannUSchedlowskiMExtonMS: Orgasm-induced prolactin secretion: feedback control of sexual drive?Neurosci. Biobehav. Rev.26, 31–44 (2002).
37.
PfausJGGorzalkaBB: Opioids and sexual behavior. Neurosci. Biobehav. Rev.11, 1–34 (1987).
38.
LeiblumSSymondsTMooreJSoniPSteinbergSSissonMA: Methodology study to develop and validate a screener for hypoactive sexual desire disorder in postmenopausal women. J. Sex. Med.3, 455–464 (2006).
39.
RustJDerogatisLRodenbergCKoochakiPSchmittSGolombokS: Development and validation of a new screening tool for hypoactive sexual desire disorder: the Brief Profile of Female Sexual Function (B-PFSF). Gynecol. Endocrinol.23, 638–644 (2007).
40.
ClaytonAHGoldfischerERGoldsteinIDeRogatisLLewis-D'AgostinoDPykeR: Validation of the Decreased Sexual Desire Screener (DSDS): a brief diagnostic instrument for generalized acquired female Hypoactive Sexual Desire Disorder (HSDD). J. Sex. Med.6, 730–738 (2009).
41.
A prospective nontreatment multicenter study in order to validity of the decreased sexual desire screener for diagnosing generalized acquired HSDD in women.
42.
GoldfischerERClaytonAHGoldsteinILewis-D'AgostinoDPykeR: Decreased Sexual Desire Screener (DSDS) for diagnosis of hypoactive sexual desire disorder in women. Obstet. Gynecol.111(Suppl.), 109S (2008).
43.
NappiREDeanJHebertAPykeR: Decreased Sexual Desire Screener (DSDS) for diagnosis of Hypoactive Sexual Desire Disorder (HSDD) in European women. J. Sex. Med.6(Suppl. 2), 46 (2009).
44.
Al-AzzawiFBitzerJBrandenburgU: Therapeutic options for postmenopausal female sexual dysfunction. Climacteric13(2), 103–120 (2010).
45.
A review of pharmacological and nonpharmacological therapies available for postmenopausal female sexual dysfunction focusing onpractical recommendations.
46.
McCabeMP: Evaluation of a cognitive behavior therapy program for people with sexual dysfunction. J. Sex. Marital Ther.27, 259–271 (2001).
47.
TrudelGMarchandARavartMAubinSTurgeonLFortierP: The effect of a cognitive-behavioral treatment program on hypoactive sexual desire in women. Sex Relat. Ther.16, 145–164 (2001).
48.
SherwinBBGelfandMMBrenderW: Androgen enhances sexual motivation in females: a prospective, crossover study of sex steroid administration in the surgical menopause. Psychosom. Med.47(4), 339–51 (1985).
49.
A prospective, crossover investigation onandrogens and sexual motivation and sexual activity.
50.
ArltWCalliesFvan VlijmenJC: Dehydroepiandrosterone replacement in women with adrenal insufficiency. N. Engl. J. Med.341(14), 1013–1020 (1999).
51.
BachmannGBancroftJBraunsteinG: Princeton: female androgen insufficiency: the Princeton consensus statement on definition, classification, and assessment. Fertil. Steril.77(4), 660–665 (2002).
52.
WiermanMEBassonRDavisSR: Androgen therapy in women: an Endocrine Society Clinical Practice guideline. J. Clin. Endocrinol. Metab.91(10), 3697–3610 (2006).
53.
Guidelines for the therapeutic use of androgens in women.
54.
TraishAGuayATSparkRF: Testosterone therapy in women study group: are the endocrine society's clinical practice guidelines on androgen therapy in women misguided? A commentary. J. Sex. Med.4(5), 1223–1234; discussion 1234–1235 (2007).
55.
JuddHLJuddGELucasWEYenSS: Endocrine function of the postmenopausal ovary: concentration of androgens and estrogens in ovarian and peripheral vein blood. J. Clin. Endocrinol. Metab.39(6), 1020–1024 (1974).
56.
LoboRA: Androgens in postmenopausal women: production, possible role, and replacement options. Obstet. Gynecol. Surv.56(6), 361–76 (2001).
57.
A review focuses on the physiology of androgens in postmenopausal women.
58.
DunnJFNisulaBCRodbardD: Transport of steroid hormones: binding of 21 endogenous steroids to both testosterone-binding globulin and corticosteroid-binding globulin in human plasma. J. Clin. Endocrinol. Metab.53(1), 58–68 (1981).
59.
LabrieFLuu-TheVBélangerA: Is dehydroepiandrosterone a hormone?J. Endocrinol.187(2), 169–196 (2005).
60.
PalaciosS: Androgens and female sexual function. Maturitas57(1), 61–65 (2007).
61.
Relevant review on the evidence and limitations in the androgens studies on female sexual function.
62.
DavisonSLBellRDonathSMontaltoJGDavisSR: Androgen Levels in Adult Females: changes with age, menopause, and oophorectomy. J. Clin. Endocrinol. Metab.90, 3847–3853 (2005).
63.
LoboRARosenRCYangHMBlockBVan Der HoopRG: Comparative effects of oral esterified estrogens with and without methyltestosterone on endocrine profiles and dimensions of sexual function in postmenopausal women with hypoactive sexual desire. Fertil. Steril.79(6), 1341–1352 (2003).
64.
Double-blind randomized trial to investigate the hormonal effects of the combination of oral esterified estrogens and methyltestosterone on hypoactive sexual desire.
65.
BraunsteinGDSundwallDAKatzM: Safety and efficacy of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial. Arch. Intern. Med.165(14), 1582–1589 (2005).
66.
The first randomized, double-blind, placebo-controlled trial to study the efficacy and safety of trasdermal testosterone in treating HSDD in surgically menopausal women.
67.
BusterJEKingsbergSAAguirreO: Testosterone patch for low sexual desire in surgically menopausal women: a randomized trial. Obstet. Gynecol.105(5 Pt 1), 944–952 (2005).
68.
Assesed the efficacy and safety of a 300 μg/d testosterone patch for the treatment of HSDD in surgically menopausal women on concomitant oestrogen therapy.
69.
SimonJBraunsteinGNachtigallL: Testosterone patch increases sexual activity and desire in surgically menopausal women with hypoactive sexual desire disorder. J. Clin. Endocrinol. Metab.90(9), 5226–5233 (2005).
70.
The objective of this double-blind, placebo-controlled trial was to evaluate the efficacy and safety of a testosterone patch in surgically menopausal women with HSDD.
71.
DavisSRvan der MoorenMJvan LunsenRH: Efficacy and safety of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial. Menopause13(3), 387–396 (2006).
72.
Investigated the efficacy and safety of a testosterone patch in surgically menopausal women receiving concurrent trasdermal estrogens.
73.
ShifrenJLDavisSRMoreauM: Testosterone patch for the treatment of hypoactive sexual desire disorder in naturally menopausal women: results from the INTIMATE NM1 Study. Menopause13(5), 770–779 (2006).
74.
Trial evaluating the efficacy and safety of a testosterone patch for the treatment of women with HSDD afternatural menopause.
75.
DavisSRMoreauMKrollR; APHRODITE Study Team: Testosterone for low libido in postmenopausal women not taking estrogen. N. Engl. J. Med.359(19), 2005–2017 (2008).
76.
Double-blind, placebo controlled trial in postmenopausal women with a testosterone patch and not receiving oestrogen therapy.
77.
Barrett-ConnorEGoodman-GrueenD: Prospective study of endogenous sex hormones and fatal cardiovascular disease in postmenopausal women. BMJ311(7014), 1193–1196 (1995).
78.
GelfandMMWiitaB: Androgen and estrogen-androgen hormone replacement therapy: a review of the safety literalture, 1941 to 1996. Clin. Ther.19(3), 383–404; discussion 367–368 (1997).
79.
TuckermanEMOkonMALiTLairdSM: Do androgens have a direct effect on endometrial function? An in vitro study. Fertil. Steril.74(4), 771–779 (2000).
80.
YamakiJYamamotoTOkadaH: Aromatization of androstenedione by normal and neoplastic endometrium of the uterus. J. Steroid Biochem.22(1), 63–66 (1985).
81.
YamamotoTKitawakiJUrabeM: Estrogen productivity of endometrium and endometrial cancer tissue; influence of aromatase on proliferation of endometrial cancer cells. J. Steroid Biochem. Mol. Biol.44(4–6), 463–468 (1993).
82.
BitzerJKenemansPMueckAO: FSD education Group: Breast cancer risk in postmenopausal women using testosterone in combination with hormone replacement therapy. Maturitas59(3), 209–218 (2008).
83.
RosenfieldRL: Pilosebaceous physiology in relation to hirsutism and acne. Clin. Endocrinol. Metab.15(2), 341–362 (1986).
84.
SherwinBB: Randomized clinical trials of combined estrogen-androgen preparations: effects on sexual functioning. Fertil. Steril.77(Suppl. 4) S49–S54 (2002).
85.
CardozoLGibbDMStuddJWTuckSMThomMHCooperDJ: The use of hormone implants for climacteric symptoms. Am. J. Obstet. Gynecol.148(3), 336–337 (1984).
86.
DavisSRMcCloudPStraussBJBurgerH: Testosterone enhances estradiol's effects on postmenopausal bone density and sexuality. Maturitas21(3), 227–236 (1995).
87.
StahlSMSommerBAllersKA: Multifunctional pharmacology of flibanserin: possible mechanism of therapeutic ation in hypoactive sexual desire disorder. J. Sex. Med. (2010) (Epub ahead of print).
88.
JollyEClaytonAHThorpJ: Efficacy of flibanserin 100 mg qhs as a potential treatment for Hypoactive Sexual Desire Disorder in premenopausal women. Presented at: The European Society of Sexual Medicine Congress.Lyon, France, November 2009.
89.
JollyEClaytonAHThorpJ: Efficacy of flibanserin 100 mg qhs as a potential treatment for hypoactive sexual desire disorder in premenopausal women. J. Sex. Med.6(Suppl. 5), 465 (2009).
90.
Relevant clinical trial on the efficacy of flibanserin. The results suggested a potential benefit on sexual function.
91.
JollyEClaytonAHThorpJ: Safety and tolerability of flibanserin in premenopausal women with Hypoactive Sexual Desire Disorder. J. Sex. Med.6(Suppl. 5), 409 (2009).
92.
Relevant clinical trial on the safety of flibanserin.
